NEW YORK (GenomeWeb) - DiagnoCure today reported a 3 percent decrease year over year in its fiscal 2015 first quarter revenues.

For the three months ended Jan. 31, DiagnoCure's total revenues retreated to C$142,915 (US$131,529) from C$146,969 in the year-ago quarter.

Excluding the effects of currency exchange, total revenues decreased by 15 percent to C$112,381 for the first quarter of 2015 compared to C$132,178 in Q1 2014. This decrease is mainly attributable to a 32 percent year over year drop in PCA3 European royalty revenues, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.